What's new

On Friday 21 June 2019, ARPANSA was notified of a radiation contamination event at the Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine (ANM) production facility in Lucas Heights, New South Wales.

ARPANSA is aware that there is a lot of concerning misinformation circulating throughout the community about the possible impacts of Australia’s planned roll-out of the 5G mobile network.

We have published the Guide for Radiation Protection in Emergency Exposure Situations.

ARPANSA’s CEO, Dr Carl-Magnus Larsson has amended a licence issued to the Australian Nuclear Science and Technology Organisation (ANSTO) to operate the ANSTO Nuclear Medicine (ANM) facility.

​​​​​​​Recently, ARPANSA co-authored a new study which found that modern airline pilots registered in Australia, appear not to be at higher risk of developing invasive melanoma than the rest of the population.

We’re pleased to be partnering with the Central Highlands Regional Council to establish Queensland’s fourth location for collection of real time ultraviolet (UV) data.

ARPANSA has granted the Australian Nuclear Science and Technology Organisation (ANSTO) an amended license to allow for the limited production of molybdenum-99 in order to sustain supply.

At ARPANSA, we set the safety standard sets limits for exposure to radio frequency (RF) electromagnetic energy (EME) that is emitted by mobile phones and other wireless technologies. These limits are set well below levels at which harm to people may occur. The operating frequencies of the 5G network are included within the limits set by the ARPANSA safety standard.

We’re excited to announce that we have installed a new linear accelerator (linac) at ARPANSA, to continue ensuring any Australians undergoing medical procedures receive the correct amount of radiation.

The Governor-General has reappointed Dr Carl-Magnus Larsson as the CEO of ARPANSA for a term of three years.

We’ve released national advice for light-based cosmetic treatments in Australia for both patients and practitioners. 

The final report for the Integrated Regulatory Review Service (IRRS) mission to Australia has been released.

ARPANSA scientists have reviewed the recent National Toxicology Program (NTP) animal studies which looked at whether exposure to radiofrequency (RF) radiation causes any health effects, including cancer, in rats and mice.

The ARPANS Regulations 1999 and ARPANS Licence Charges Regulations 2000 have been repealed and replaced.

A study led by ARPANSA, published with the British Medical Journal Open, found no link between the use of mobile phones in Australia and incidence of brain cancers.

Today, the Integrated Regulatory Review Service (IRRS) mission was officially opened at ARPANSA. Officials emphasised the mission, reviewing Australia’s nuclear protection and radiation safety regulatory framework, shows international openness and transparency and a commitment to improvement.